<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01320345</url>
  </required_header>
  <id_info>
    <org_study_id>FAME0001</org_study_id>
    <secondary_id>ACTRN12611000249954</secondary_id>
    <nct_id>NCT01320345</nct_id>
  </id_info>
  <brief_title>The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye.</brief_title>
  <acronym>FAME 1 EYE</acronym>
  <official_title>A Randomised Trial to Evaluate the Efficacy on Retinopathy and Safety of Fenofibrate in Adults With Type 1 Diabetes. A Multicentre Double-blind Placebo-controlled Study in Australia and Internationally.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sydney</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Health and Medical Research Council, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mylan Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sydney</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the potential benefits of 145 mg of daily
      fenofibrate in adults with type 1 diabetes mellitus and pre-existing non-proliferative
      diabetic retinopathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetes is the most common cause of adult onset blindness. Irreversible vision loss is a
      most feared complication of diabetes. Fenofibrate is a blood fat lowering drug available in
      Australia and has been shown to reduce eye damage in people with Type 2 diabetes by 35-40%,
      and to prevent eye damage in Type 1 diabetic animal models. This study will evaluate the
      potential benefits of oral Fenofibrate 145mg once daily for 12 months in 300 adults with Type
      1 diabetes mellitus who are at high risk of eye damage. This study will evaluate the
      potential benefits of fenofibrate in 450 adults with Type 1 diabetes who are at high risk of
      eye damage.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 3, 2016</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of clinical significant retinopathy progression.</measure>
    <time_frame>At baseline, 12 m post-randomisation, 24 m post-randomisation and the end of study visit (which is on average 36 months post-randomisation).</time_frame>
    <description>Occurrence of clinical significant retinopathy progression, defined as a 2-step progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Albuminuria.</measure>
    <time_frame>At baseline, date of randomisation, 3 m post-randomisation, 12 m post-randomisation, 24 m post-randomisation, the end of study visit (which is on average 36 months post-randomisation) and wash-out visit.</time_frame>
    <description>Albuminuria measured as urinary albumin:creatinine ratio.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity.</measure>
    <time_frame>At baseline, 12 m post-randomisation, 24 m post-randomisation and the end of study visit (which is on average 36 months post-randomisation).</time_frame>
    <description>Visual acuity using Snellen Chart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal nerve damage.</measure>
    <time_frame>At baseline, 12 m post-randomisation, 24 m post-randomisation and the end of study visit (which is on average 36 months post-randomisation).</time_frame>
    <description>Corneal confocal microscopic measurement of neural damage (only assessed in a representative subset of the participants at sites with the specialised confocal microscope).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated glomerular filtration rate.</measure>
    <time_frame>At baseline, 12 m post-randomisation, 24 m post-randomisation and the end of study visit (which is on average 36 months post-randomisation).</time_frame>
    <description>Estimated glomerular filtration rate using Modification of Diet in Renal Disease (MDRD) formula.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral neuropathy status.sensation.</measure>
    <time_frame>At baseline, 12 m post-randomisation, 24 m post-randomisation and the end of study visit (which is on average 36 months post-randomisation).</time_frame>
    <description>Peripheral neuropathy status assessed by temperature sensation and monofilament sensation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular function.</measure>
    <time_frame>At baseline, 12 m post-randomisation, 24 m post-randomisation and the end of study visit (which is on average 36 months post-randomisation).</time_frame>
    <description>Vascular function using non-invasive pulse wave techniques and plethysmography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood lipids and biomarkers in plasma.</measure>
    <time_frame>At baseline, 12 m post-randomisation, 24 m post-randomisation and the end of study visit (which is on average 36 months post-randomisation) and wash-out visit.</time_frame>
    <description>Blood lipids and biomarkers in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cardiovascular events.</measure>
    <time_frame>As reported throughout the study.</time_frame>
    <description>Total cardiovascular events including myocardial infarction, stroke, sudden cardiac death, hospitalisation for acute coronary syndrome or any revascularisation events. These events are reported post-hoc by site to the sponsor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of foot ulcer and non-traumatic amputation.</measure>
    <time_frame>On study completion.</time_frame>
    <description>Frequency of foot ulcer and non-traumatic amputation. These events are reported post-hoc by site to the sponsor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macular volume.</measure>
    <time_frame>On study completion.</time_frame>
    <description>Macular volume measured by Optical Coherence Tomography (OCT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autonomic neuropathy.</measure>
    <time_frame>At baseline, 12 m post-randomisation, 24 m post-randomisation and the end of study visit (which is on average 36 months post-randomisation).</time_frame>
    <description>Autonomic neuropathy (QTc and R-R intervals) on annual ECGs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of clinically significant macula oedema (CSME).</measure>
    <time_frame>At baseline, 12 m post-randomisation, 24 m post-randomisation and the end of study visit (which is on average 36 months post-randomisation).</time_frame>
    <description>Occurrence of clinically significant macula oedema (CSME) measured by optical coherence tomography and retinal photography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for laser surgery.</measure>
    <time_frame>At baseline, 12 m post-randomisation, 24 m post-randomisation and the end of study visit (which is on average 36 months post-randomisation).</time_frame>
    <description>Need for laser surgery measured by progression of retinopathy per standard ophthalmological assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for intraocular anti-VEGF (vascular endothelial growth factor) injection.</measure>
    <time_frame>At baseline, 12 m post-randomisation, 24 m post-randomisation and the end of study visit (which is on average 36 months post-randomisation).</time_frame>
    <description>Need for intraocular anti-VEGF (vascular endothelial growth factor) injection as per standard ophthalmological assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for corticosteroid therapy.</measure>
    <time_frame>At baseline, 12 m post-randomisation, 24 m post-randomisation and the end of study visit (which is on average 36 months post-randomisation).</time_frame>
    <description>Need for corticosteroid therapy to treat progressive retinopathy as per standard ophthalmological assessments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for vitrectomy procedure.</measure>
    <time_frame>At baseline, 12 m post-randomisation, 24 m post-randomisation and the end of study visit (which is on average 36 months post-randomisation).</time_frame>
    <description>Need for vitrectomy procedure as per standard ophthalmological assessment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <condition>Diabetic Retinopathy</condition>
  <condition>Diabetic Nephropathies</condition>
  <arm_group>
    <arm_group_label>Fenofibrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>145 mg tablet of fenofibrate administered daily for 36 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inert lactose tablet (otherwise matching active) administered daily for 36 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate</intervention_name>
    <description>145 mg tablet of fenofibrate administered once daily for 36 months.</description>
    <arm_group_label>Fenofibrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inert lactose placebo</intervention_name>
    <description>Insert lactose tablet matching active tablet administered once daily for 36 months.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria (for the main study):

          1. Men or non-pregnant women (on acceptable contraception) with T1D* according to
             standard criteria:

               -  T1D defined as either (1) T1D diagnosed below 40 years of age and insulin therapy
                  commencing within one year of T1D diagnosis, or (2) T1D diagnosed before, at or
                  after 40 years of age along with: i) Documented history of ketoacidosis, and/or
                  ii) Documented history of very low or undetectable C-peptide (fasting &lt;200 nmol/L
                  or 0.2 pmol/L), and/or iii) Documented history of T1D related autoantibody/ies
                  (anti-Glutamic acid decarboxylase, anti-A2, anti-ZnT8).

          2. Age 18 years or over;

          3. Estimated glomerular filtration rate (eGFR) must exceed 30 ml/min/1.73m2;

          4. Must have at least one eligible eye with non-proliferative retinopathy (ETDRS score
             35-53 inclusive) confirmed by current retinal photography within the last 3 months
             (irrespective of prior laser therapy). Note: Any eye having undergone prior
             pan-retinal laser therapy is not eligible, but prior focal, macular or grid laser does
             not exclude that eye from eligibility.;

          5. All types of insulin therapy, with no restriction by level of HbA1c;

          6. Willing and able to comply with all study requirements, including treatment,
             assessment and clinic visit attendances;

          7. Able to personally read and understand the Participant Information and Consent Form
             and provide written, signed and dated informed consent to participate in the study.

        Eligibility criteria for the reference group is limited to age and gender matched
        individuals who do not have T1D.

        Exclusion criteria:

          1. Definite indication for or contraindications to fibrate treatment (Other lipid drugs
             [e.g. statins, ezetimibe, fish oils] are allowed.);

          2. Need for bilateral intra-ocular treatment or laser photocoagulation therapy within the
             next 3 months (this exclusion only applies to retinal laser photocoagulation treatment
             to the posterior pole i.e. laser correction of corneas for short-sightedness is NOT an
             exclusion criterion);

          3. Prior bilateral pan-retinal photocoagulation (PRP) treatment for diabetic retinopathy;

          4. Prior bilateral intra-ocular injection(s) within the last 6 months;

          5. Bilateral cataract surgery within the last 6 months;

          6. Planned bilateral cataract surgery within the next 12 months;

          7. History of any other non-diabetic eye disease that is or is likely to affect bilateral
             vision;

          8. History of photosensitive skin rash or myositis;

          9. Abnormal thyroid function (untreated);

         10. Liver function tests exceeding 3x upper limit of normal (ULN);

         11. Persistent elevated unexplained blood creatinine phosphokinase level above normal
             range;

         12. Documented fasting triglycerides (TG) levels &gt;6.5 mmol/L;

         13. History of pancreatitis, deep vein thrombosis (DVT) or pulmonary embolism;

         14. Use of investigational drugs in the prior 8 weeks;

         15. Any unstable condition in last 3 months including active sepsis, diabetic
             ketoacidosis;

         16. Myocardial infarction (MI), unstable angina, stroke or heart failure within last 6
             months;

         17. Diagnosed cancer with ongoing treatment or prognosis anticipated at &lt;5 years;

         18. Any obstacle to regular follow-up including scheduled clinic attendances;

         19. Prior or planned organ transplantation (including islet cells) with subsequent
             continued immunosuppression therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Keech, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>NHMRC Clinical Trials Centre, The University of Sydney</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alicia Jenkins, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>NHMRC Clinical Trials Centre, The University of Sydney</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liping Li</last_name>
    <phone>+61 2 9562 5000</phone>
    <email>fame1eye@ctc.usyd.edu.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephania Noonan</last_name>
      <email>Stephanie.Noonan@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Stephen Twigg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Concord Repatriation General Hospital</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Syvlia Mallo</last_name>
    </contact>
    <investigator>
      <last_name>Avinash Suryawanshi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Garvan Institute of Medical Research</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Richens</last_name>
      <email>r.richens@garvan.org.au</email>
    </contact>
    <investigator>
      <last_name>Jerry Greenfield</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Retina Associates - South West Retina</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tania Tsang</last_name>
      <email>tania@retina.com.au</email>
    </contact>
    <investigator>
      <last_name>Gerald Liew</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hunter Diabetes Centre</name>
      <address>
        <city>Merewether</city>
        <state>New South Wales</state>
        <zip>2291</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maureen Rae</last_name>
      <email>maureen@hunterdiabetes.com.au</email>
    </contact>
    <investigator>
      <last_name>Claire Morbey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>Saint Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Doyle</last_name>
      <email>Jean.doyle@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Greg Fulcher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Gilroy</last_name>
      <email>Deborah.Gilroy@health.qld.gov.au</email>
    </contact>
    <investigator>
      <last_name>Anthony Russell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Healy</last_name>
    </contact>
    <investigator>
      <last_name>Liza Phillips</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern Adelaide Diabetes and Endocrine Services</name>
      <address>
        <city>Oaklands Park</city>
        <state>South Australia</state>
        <zip>5046</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fahriya Zandari</last_name>
      <email>fahriya.zandari@sa.gov.au</email>
    </contact>
    <investigator>
      <last_name>Stephen Stranks</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barwon Health</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louise O'Callaghan</last_name>
      <email>locallaghan@barwonhealth.org.au</email>
    </contact>
    <investigator>
      <last_name>Mark Kotowicz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heidelberg Repatriation Hospital</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3081</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariam Hachem</last_name>
      <email>mariam.hachem@unimelb.edu.au</email>
    </contact>
    <investigator>
      <last_name>Elif Ekinci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baker Heart and Diabetes Institute</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Boyle</last_name>
      <email>erin.boyle@baker.edu.au</email>
    </contact>
    <investigator>
      <last_name>Neale Cohen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital Melbourne</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue Kent</last_name>
      <email>sue.kent@unimelb.edu.au</email>
    </contact>
    <investigator>
      <last_name>David O'Neal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fremantly Hospital</name>
      <address>
        <city>Fremantle</city>
        <state>Western Australia</state>
        <zip>6160</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle England</last_name>
      <email>Michelle.england@uwa.edu.au</email>
    </contact>
    <investigator>
      <last_name>Tim Davis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Auckland Diabetes Centre</name>
      <address>
        <city>Auckland</city>
        <zip>1051</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tricha Ball</last_name>
      <email>TrichaB@adhb.govt.nz</email>
    </contact>
    <investigator>
      <last_name>Manish Khanolkar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prasanna Karunasekera</last_name>
      <email>Prasanna.Karunasekera@cdhb.health.nz</email>
    </contact>
    <investigator>
      <last_name>Russell Scott</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 18, 2011</study_first_submitted>
  <study_first_submitted_qc>March 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2011</study_first_posted>
  <last_update_submitted>September 19, 2019</last_update_submitted>
  <last_update_submitted_qc>September 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Type 1 Diabetes Mellitus</keyword>
  <keyword>Retinopathy</keyword>
  <keyword>Diabetic Nephropathy</keyword>
  <keyword>Fenofibrate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

